58 related articles for article (PubMed ID: 8451040)
21. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
Albany C; Brames MJ; Fausel C; Johnson CS; Picus J; Einhorn LH
J Clin Oncol; 2012 Nov; 30(32):3998-4003. PubMed ID: 22915652
[TBL] [Abstract][Full Text] [Related]
22. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research.
Roila F; Tonato M; Basurto C; Bella M; Passalacqua R; Morsia D; DiCostanzo F; Donati D; Ballatori E; Tognoni G
J Clin Oncol; 1987 Jan; 5(1):141-9. PubMed ID: 3543234
[TBL] [Abstract][Full Text] [Related]
23. Immediate termination of intractable vomiting induced by cisplatin combination chemotherapy using an intensive five-drug antiemetic regimen.
Plezia PM; Alberts DS; Kessler J; Aapro MS; Graham V; Surwit EA
Cancer Treat Rep; 1984 Dec; 68(12):1493-5. PubMed ID: 6542448
[TBL] [Abstract][Full Text] [Related]
24. Comparative evaluation of the clinical efficacy and safety of ondansetron and metoclopramide in the prophylaxis of emesis induced by cancer chemotherapy regimens including cisplatin.
Advani SH; Gopal R; Dhar AK; Lal HM; Cooverji ND
J Assoc Physicians India; 1996 Feb; 44(2):127-30. PubMed ID: 10999066
[TBL] [Abstract][Full Text] [Related]
25. Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Support Care Cancer; 1994 May; 2(3):167-70. PubMed ID: 8032702
[TBL] [Abstract][Full Text] [Related]
26. High-dose dexamethasone and high-dose metoclopramide versus high-dose dexamethasone and sulpiride in the management of cisplatin-induced emesis.
Rosenblatt E; Lev LM; Robinson E
Oncology; 1988; 45(4):297-9. PubMed ID: 3387033
[TBL] [Abstract][Full Text] [Related]
27. Antiemetic efficacy of high-dose intravenous metoclopramide and dexamethasone in patients receiving cisplatin-based chemotherapy: a randomized controlled trial.
Shinkai T; Saijo N; Eguchi K; Sasaki Y; Tamura T; Tominaga K; Sakurai M; Sano T; Taito H; Takahashi H
Jpn J Clin Oncol; 1986 Sep; 16(3):279-87. PubMed ID: 3534348
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the antiemetic efficacy of two high-dose benzamides, metoclopramide and alizapride, against cisplatin-induced emesis.
Saller R; Hellenbrecht D
Cancer Treat Rep; 1985 Nov; 69(11):1301-3. PubMed ID: 3912040
[TBL] [Abstract][Full Text] [Related]
29. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research.
J Clin Oncol; 1993 Dec; 11(12):2396-404. PubMed ID: 8246029
[TBL] [Abstract][Full Text] [Related]
30. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
Markham A; Sorkin EM
Drugs; 1993 Jun; 45(6):931-952. PubMed ID: 7691500
[TBL] [Abstract][Full Text] [Related]
31. [Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone].
Senn HJ; Köhler M; Glaus A; Bachmann-Mettler I; Weigand W
Dtsch Med Wochenschr; 1986 Jan; 111(4):129-35. PubMed ID: 3510848
[TBL] [Abstract][Full Text] [Related]
32. Antiemetic efficacy of moderately high-dose metoclopramide in patients receiving varying doses of cisplatin. Controlled comparison with a combination of methylprednisolone and metoclopramide.
Ell C; König HJ; Brockmann P; Domschke S; Domschke W
Oncology; 1985; 42(6):354-7. PubMed ID: 4069550
[TBL] [Abstract][Full Text] [Related]
33. [The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial].
Zeng W; Zhou J; Zhang P
Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):294-7. PubMed ID: 7587900
[TBL] [Abstract][Full Text] [Related]
34. Effective control of moderate-dose cisplatin-induced emesis by a short-course regimen including metoclopramide, chlorpromazine and hydrocortisone: results of a randomized trial with metoclopramide alone.
Pollera CF; Calabresi F
Oncology; 1989; 46(4):238-44. PubMed ID: 2740067
[TBL] [Abstract][Full Text] [Related]
35. A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind study.
Carr BI; Bertrand M; Browning S; Doroshow JH; Presant C; Pulone B; Hill LR
J Clin Oncol; 1985 Aug; 3(8):1127-32. PubMed ID: 4040552
[TBL] [Abstract][Full Text] [Related]
36. A pilot study of metoclopramide, dexamethasone, diphenhydramine and lorazepam in prevention of nausea and vomiting in cisplatin-treated male patients.
Roila F; Basurto C; Bracarda S; Picciafuoco M; Ballatori E; Del Favero A; Tonato M
Oncology; 1990; 47(5):415-7. PubMed ID: 2216296
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin.
Gralla RJ; Rittenberg C; Peralta M; Lettow L; Cronin M
Oncology; 1996 Jun; 53 Suppl 1():86-91. PubMed ID: 8692558
[TBL] [Abstract][Full Text] [Related]
38. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of continuous high-dose metoclopramide in patients receiving daily cisplatin infusions.
Saab GA; Ibrahim N; Azouri N
Cancer Treat Rep; 1987 Oct; 71(10):979-80. PubMed ID: 3652059
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the antiemetic activity of bromopride in cancer patients treated with i.v. CMF.
Roila F; Minotti V; Ballatori E; Basurto C; Tonato M
Tumori; 1985 Oct; 71(5):455-8. PubMed ID: 3840612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
